Related Experiment Video
Updated: Jul 1, 2025
07:31
A Model of Cardiac Remodeling Through Constriction of the Abdominal Aorta in Rats
Published on: December 2, 2016
10.0K
Mildly Reduced Renal Function Is Associated With Increased Heart Failure Admissions in Patients With Hypertrophic
Nan Young Bae1, Tae-Min Rhee2, Chan Soon Park1
1Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.
Journal of Korean Medical Science
|March 5, 2024
Summary
Even mildly reduced kidney function in hypertrophic cardiomyopathy (HCM) patients significantly increases the risk of major adverse cardiovascular events (MACEs), particularly heart failure hospitalizations.
Area of Science:
- Cardiology
- Nephrology
- Clinical Outcomes Research
Background:
- The link between impaired kidney function and cardiovascular prognosis in hypertrophic cardiomyopathy (HCM) is not well-established.
- This study investigates the association between reduced estimated glomerular filtration rate (eGFR) and adverse cardiovascular outcomes in HCM patients.
Purpose of the Study:
- To determine if mildly reduced renal function is associated with worse prognosis in patients diagnosed with hypertrophic cardiomyopathy.
- To quantify the risk of major adverse cardiovascular events (MACEs) in HCM patients across different stages of kidney function.
Main Methods:
- 1,756 patients with HCM were analyzed, excluding those on dialysis or with prior heart failure or stroke.
- Patients were stratified by eGFR into stage I (≥90), stage II (60-89), and stage III-V (<60 mL/min/1.73 m²).
- Major adverse cardiovascular events (MACEs), including cardiovascular death, heart failure hospitalization (HHF), and stroke, were tracked over a median of 4.0 years using multivariable Cox regression.
Main Results:
- Patients with stage III-V renal function had a 2.71-fold higher risk of MACEs (P=0.003), driven by cardiovascular death and HHF.
- Even stage II renal function (eGFR 60-89 mL/min/1.73 m²) was linked to a 2.21-fold increased MACE risk (P=0.008) and a 2.62-fold higher HHF risk (P=0.012) compared to stage I.
- The findings highlight a significant association between reduced eGFR and adverse cardiovascular outcomes in the HCM cohort.
Conclusions:
- Mildly reduced renal function (eGFR 60-89 mL/min/1.73 m²) in HCM patients is associated with a significantly elevated risk of MACEs.
- Hospitalization for heart failure (HHF) was a primary driver of increased MACEs in patients with reduced renal function.
- These results underscore the importance of monitoring renal function in HCM management for improved cardiovascular risk stratification.
Related Concept Videos
01:17Pathophysiology of Heart Failure
1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
01:22Heart Failure Drugs: Diuretics
375
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
375
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
429
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
429
01:26Imbalances in Cardiac Output
1.4K
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
1.4K
01:22Heart Failure Drugs: β-Blockers
338
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
338
01:26Heart Failure Drugs: Inotropic Agents
586
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
586